depression

9511213674_31a3c06cc7_z

Introduction

Clinical, unipolar depression is more than just feeling low for a day or two.

Depression is characterised as episodes of sadness, loss of interest and pleasure, often including feelings of low self-worth. Depression can also include a range of physiological symptoms, such as fatigue, pain, diminished appetite, lack of interest in sex, disturbed sleep, and poor concentration.

The World Health Organisation estimates that, globally, as many as 350 million people are affected at any given time, with one person in 20 reporting an episode of depression in a 12 month period (in a global sample of 17 countries). They describe depression as the leading cause of disability worldwide.

What we know already

We know that, despite the considerable global burden of depression, not everybody receives treatment, with figures ranging from 50% to 10% in less developed countries.

Evidence suggests that combined psychological and pharmacological treatments seem to work well. Broadly, we know that psychotherapies work in many cases – but not every time. We know that neurochemical factors, such as serotonergic dysfunction, play an important role in depression, which goes a long way in explaining the efficacy of SSRI treatments.

We also know that depression has a nasty habit of recurrence, and some psychological interventions, such as Mindfulness-Based Cognitive Therapy (MBCT) is recommended particularly for people who have experienced multiple episodes of depression, but not are currently severely depressed.

We know that people living with chronic physical illness are more likely to experience depression, and this combination is linked with poorer clinical outcomes.

Importantly though, we know that people with depression can still enjoy themselves, and a common misconception in depression is that people feel totally awful all of the time.

Areas of uncertainty

There is much still to determine. For example, we know that depression is hereditable, however the extent of heredity versus environmental influences are unclear.

We are also unsure as to the precise mechanisms that determine those who respond best to treatments, be they psychopharmacological, or psychological, or both.

What’s in the pipeline?

Despite advances in our understanding of depression, and how it is treated, it remains a highly recurrent difficulty, with many people not achieving complete remission between episodes.

Preventative interventions, either physiological, or psychological, may improve people’s resilience to depression, particularly those identified as being highly prone.

References

Cuijpers, P. (2015). Psychotherapies for adult depression: recent developments. Current Opinion in Psychiatry, 28, 24-29. [Abstract]

Naylor, C., Parsonage, M., McDaid, D., Knapp, M., Fossey, M. and Galea, A. (2012) Long-term conditions and mental health: the cost of co-morbidities. The King’s Fund, London, UK [PDF]

World Health Organisation (2015).Factsheet 369: Depression [Link]

Photo Credits

Sascha Kohlmann CC BY 2.0

Acknowledgement

Written by: Patrick Kennedy-Williams
Reviewed by:
Last updated: Nov 2015
Review due: Sep 2016

Our depression Blogs

How sleep changes across later life, and what it means for mental health

feat

A large UK Biobank study tracked sleep in over 77,000 adults. Here’s what the data reveals about age, sex and mood.

[read the full story...]

Chronic pain in mental disorders: a widely overlooked comorbidity

Mature,Woman,Suffering,From,Back,Pain,On,Beige,Background

Chronic pain is highly common across mental disorders, yet routinely overlooked. This umbrella review of nearly a million people makes the case for integrated care.

[read the full story...]

Tackling loneliness could reduce depression for sexual minority older adults

age-cymru-4fr-FiSDAOk-unsplash

Loneliness accounted for 15% of the higher depression risk in sexual minority older adults, a new English cohort study finds, pointing to a modifiable pathway.

[read the full story...]

MDMA-assisted therapy for depression: a promising but early first step

feat

A small proof-of-principle trial suggests MDMA-assisted therapy may be feasible and effective for depression, but open-label design and a highly pre-treated sample urge caution.

[read the full story...]

Can group singing offer lasting relief from postnatal depression?

shutterstock_1097814146-1024x512

New evidence shows Melodies for Mums outperforms standard community activities in reducing postnatal depression, with sustained effects lasting six months after the singing ends.

[read the full story...]

In the Land of the Unblind: are psychedelics really better than antidepressants?

feat

Psychedelic therapy looks impressive in trials, but when you account for the placebo effect, how does it really compare to antidepressants?

[read the full story...]

Spotting teen depression: what Brazil, Nepal and Nigeria can teach us

Short from behind of person sitting on swing with hood up

A cross-cultural study explores why depressed adolescents in Brazil, Nepal and Nigeria often slip through the net, and what we can do about it.

[read the full story...]

Active coping could protect young people from depression after adversity

High,Black,Sneakers,Isolated,On,White,Background

A new study from Latin America finds that active coping could protect young people exposed to stressful life events from developing depression and anxiety.

[read the full story...]

Body clocks and mental health: patients set the research agenda

feat

For the first time, people with lived experience, carers and clinicians have identified the top 10 research priorities for body clocks and mental health.

[read the full story...]

When the treatment doesn’t work: what predicts difficult-to-treat postpartum depression?

feat

Swedish nationwide study of 58,618 women found 6% experienced treatment-resistant postpartum depression. Risk factors included lower socioeconomic status, smoking, pre-existing health conditions, caesarean or preterm birth.

[read the full story...]